Summit Therapeutics PLC SMMT

HARMONi-GI1 is Akeso’s Phase III trial in China comparing ivonescimab plus chemotherapy to durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer. At interim analysis, the ivonescimab regimen demonstrated a statistically significant OS benefit, with PFS and ORR also meeting their secondary endpoints. Akeso generated and analyzed all data; results will be presented at the ESMO 2026 Presidential Symposium II on October 25, 2026. Ivonescimab (SMT112 in Summit's territories; AK112 outside) is a novel bispecific PD-1/VEGF inhibitor with a tetravalent design intended to enhance tumor targeting. In China it is approved for NSCLC but remains investigational in Summit's license regions. Summit notes this is the first Phase III BTC OS readout for ivonescimab and emphasizes multiple ivonescimab trials globally. Strengthens ivonescimab’s competitive profile and could positively influence Summit's development strategy and investor sentiment.

New Ivonescimab survival data raises question of whether Summit Therapeutics (SMMT) stock trades below fair value. Ivonescimab survival data can significantly shift investor views on SMMT valuation and trajectory.

Updated HARMONi data presented at WCLC 2026 shows consistent overall survival results with ivonescimab plus chemotherapy in both Western and Asian patients. Positive consistent survival data across populations strengthens ivonescimab clinical profile and approval prospects.

Summit Therapeutics and Akeso release fresh clinical study results on their PD-1/VEGF drug to counter existing doubts about its efficacy and prospects. Positive late-stage data on lead PD-1/VEGF asset can materially shift regulatory path, partnership value and share price trajectory for Summit.

Ivonescimab monotherapy achieved statistically significant and clinically meaningful superiority versus pembrolizumab monotherapy for PD-L1-positive advanced NSCLC in Akeso's HARMONi-2 trial conducted in China. Positive pivotal trial data for lead asset Ivonescimab directly strengthens SMMT's NSCLC positioning and long-term commercial outlook.

Summit Therapeutics announced Akeso reported HARMONi-2 overall survival benefit versus pembrolizumab. HARMONi-2 overall survival win versus pembrolizumab directly boosts Summit's key oncology asset and market outlook.

Summit Therapeutics (SMMT) shares surge 28% on progress with Ivonescimab. Ivonescimab progress triggers 28% stock surge and signals major pipeline advancement for SMMT.

Summit Therapeutics PLC's SMMT stock surges after its NSCLC drug demonstrates superior survival data versus Keytruda in China. Superior survival data beating Keytruda in China drives major gains and strengthens SMMT's competitive position in oncology.

Summit Therapeutics advances a therapy that challenges Merck's Keytruda in oncology, yet investor and analyst skepticism persists over its clinical edge and commercial viability. Potential competition against Keytruda could shift Summit's market position and valuation in checkpoint inhibitor space.

Summit Therapeutics claims its cancer drug outperforms Merck's. Outperformance claim versus Merck signals major competitive edge and potential market gains for Summit.

Ivonescimab monotherapy achieved statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC per Akeso's HARMONi-2 study conducted in China. Statistically significant survival advantage over pembrolizumab transforms ivonescimab's competitive position in major NSCLC market.

SMMT stock rises after Akeso reports positive Phase III results in biliary tract cancer study. Akeso Phase III win advances SMMT partnered oncology pipeline and lifts market valuation.

Summit Therapeutics (SMMT) published Phase III HARMONi results in The Lancet Oncology. Phase III trial data publication represents a pivotal clinical milestone that can drive regulatory progress and shift market valuation.

Summit Therapeutics shares rise 8.5% after positive Phase III biliary cancer trial results for Ivonescimab. Positive late-stage trial data for key drug candidate drives immediate stock gains and signals major pipeline advancement.

Guggenheim states Summit Therapeutics PLC's global lung cancer trials gain credibility following Akeso's Phase 3 data. Credibility boost for core lung cancer trials strengthens Summit's competitive position and long-term prospects.

Summit Therapeutics shares rise after partner reports positive Phase III cancer trial results. Partner's positive Phase III cancer trial results signal major advancement for Summit Therapeutics' pipeline and market prospects.

Akeso reports Phase III success for ivonescimab in second tumor type. Phase III win for ivonescimab in new indication expands SMMT pipeline value and oncology positioning.

Summit Therapeutics PLC primary analysis results from global Phase III HARMONi trial of ivonescimab plus chemotherapy published in The Lancet Oncology. Publication of Phase III results in The Lancet Oncology boosts visibility and supports regulatory and commercial progress for lead asset.

Ivonescimab plus chemotherapy achieved statistically significant overall survival benefit versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer per Akeso's single-region China trial. Positive China trial data on ivonescimab supports the drug's potential and could influence SMMT valuation modestly.

Summit Therapeutics (SMMT) and Arcus Biosciences (RCUS) pursue cancer drug partnership that may establish new treatment standard. Cancer drug partnership may significantly shift SMMT trajectory and investor sentiment through new treatment standards.

NMPA approved Ivonescimab combined with chemotherapy for first-line treatment of squamous non-small cell lung cancer in China. China approval for first-line squamous NSCLC use opens major market access and revenue path for Ivonescimab.

Summit Therapeutics expands Ivonescimab global development program via Phase II/III HARMONi-GU1 study in first-line bladder cancer. New trial broadens Ivonescimab pipeline into bladder cancer and supports future growth prospects.

Summit Therapeutics announced extended follow-up data showing stronger survival advantages for its lead cancer drug. Positive survival data on lead cancer drug signals major potential gains in clinical progress and market valuation.

Summit Therapeutics Inc highlighted a strong cash position during its Q2 2026 earnings call. Strong cash reserves support ongoing clinical programs and operations.

Summit Therapeutics updated Phase III survival data. The update raises questions on whether SMMT stock remains a bargain. Phase III survival data updates directly drive SMMT clinical progress and stock valuation shifts.

Summit Therapeutics released updated survival data for Ivonescimab from its NSCLC study. Updated survival data for lead oncology asset directly influences valuation, trial progress and investor sentiment.

New survival data from the HARMONi trial for Ivonescimab prompts questions on whether it alters Summit Therapeutics' investment outlook and competitive positioning. Pivotal trial survival results directly affect regulatory prospects and market sentiment for Summit's lead drug candidate.

Summit Therapeutics presented Q2 financial results, clinical pipeline updates and strategic plans in its earnings call. Quarterly earnings call supplies financial and pipeline details that moderately shift near-term investor sentiment and valuation.

Summit Therapeutics (SMMT) stock appears overvalued after release of fresh lung cancer data. New lung cancer data triggers negative sentiment on SMMT valuation with moderate effects on near-term share price.

Summit Therapeutics and Arcus Biosciences launch a clinical trial combining Casdatifan with Ivonescimab for kidney cancer treatment. Trial collaboration adds to Summit's oncology pipeline with moderate potential effects on future drug development.